title: Screening for prostatic cancer and its evolution within Britain.
abstract: The arguments for and against screening for prostatic cancer are frequently discussed (Albertsen PC. Screening for prostate cancer is neither appropriate nor cost-effective. Urol Clin North Am 1996; 23: 521-530; Schroder FH, Alexander FE, Bangma CH, Hugosson J, Smith DS. Screening and early detection of prostate cancer. Prostate 2000; 44: 255-263). In contrast, this paper outlines how screening became possible, why the decision was made not to initiate a national screening programme in Britain, the other pathways being pursued, and the current problems, in particular the issue of histopathology workload.
authors.forename: M C
authors.initials: MC
authors.lastname: Parkinson
authors.forename: S R J
authors.initials: SR
authors.lastname: Bott
authors.forename: R
authors.initials: R
authors.lastname: Montironi
authors.forename: J
authors.initials: J
authors.lastname: Melia
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000379:methods*; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis*; D006113:United Kingdom
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen